Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region
Abstract:: Objectives: To examine the relationship between antibody status and cycle threshold (Ct) values, the prognostic value of the latter for COVID-19 patients, and the inter-assay comparability of SARS-CoV-2 Ct values. Methods: In 347 COVID-19 inpatients, SARS-CoV-2 Ct values (via reverse tra...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971221005701 |
id |
doaj-d19d07a29ca649b6aa785dc6db12940e |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Robert Markewitz, MD Antje Torge, PhD Klaus-Peter Wandinger, MD Daniela Pauli, MD Justina Dargvainiene Andre Franke, MD Luis Bujanda, MD, PhD José Maria Marimón, PharmD Jesus M. Banales, PhD María A. Gutierrez-Stampa, MD, PhD Beatriz Nafría, BSc Ralf Junker, MD |
spellingShingle |
Robert Markewitz, MD Antje Torge, PhD Klaus-Peter Wandinger, MD Daniela Pauli, MD Justina Dargvainiene Andre Franke, MD Luis Bujanda, MD, PhD José Maria Marimón, PharmD Jesus M. Banales, PhD María A. Gutierrez-Stampa, MD, PhD Beatriz Nafría, BSc Ralf Junker, MD Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region International Journal of Infectious Diseases SARS-CoV-2 COVID-19 RT-qPCR Ct value anti-SARS-CoV-2 antibodies |
author_facet |
Robert Markewitz, MD Antje Torge, PhD Klaus-Peter Wandinger, MD Daniela Pauli, MD Justina Dargvainiene Andre Franke, MD Luis Bujanda, MD, PhD José Maria Marimón, PharmD Jesus M. Banales, PhD María A. Gutierrez-Stampa, MD, PhD Beatriz Nafría, BSc Ralf Junker, MD |
author_sort |
Robert Markewitz, MD |
title |
Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region |
title_short |
Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region |
title_full |
Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region |
title_fullStr |
Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region |
title_full_unstemmed |
Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence region |
title_sort |
analysis of sars-cov-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-sars-cov-2 antibodies from a high incidence region |
publisher |
Elsevier |
series |
International Journal of Infectious Diseases |
issn |
1201-9712 |
publishDate |
2021-09-01 |
description |
Abstract:: Objectives: To examine the relationship between antibody status and cycle threshold (Ct) values, the prognostic value of the latter for COVID-19 patients, and the inter-assay comparability of SARS-CoV-2 Ct values. Methods: In 347 COVID-19 inpatients, SARS-CoV-2 Ct values (via reverse transcription-quantitative polymerase chain reaction) on admission were compared between 2 assays and correlated with the antibody response (in the course of the disease), the clinical course and the time since onset of symptoms. Results: Ct values for 2 of 3 target genes showed significant differences between the 2 assays used (P=0.012 and P<0.0001). Ct values were significantly higher for antibody positive patients (P<0.0001) and positively correlated with the amount of time since onset of symptoms (R: 0.332–0.363; P<0.001). Patients with fatal outcomes showed higher viral loads than survivors (P<0.0001). Conclusions: Ct values depend strongly on assay used and target gene examined and should not be used as quantitative values to guide therapeutic or diagnostic decisions. The inverse association between antibody status and viral load suggests that antibodies contribute to the elimination of the virus, independent of the outcome, which is influenced by the viral load on admission and might depend more strongly on other parts of the immune response. |
topic |
SARS-CoV-2 COVID-19 RT-qPCR Ct value anti-SARS-CoV-2 antibodies |
url |
http://www.sciencedirect.com/science/article/pii/S1201971221005701 |
work_keys_str_mv |
AT robertmarkewitzmd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT antjetorgephd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT klauspeterwandingermd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT danielapaulimd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT justinadargvainiene analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT andrefrankemd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT luisbujandamdphd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT josemariamarimonpharmd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT jesusmbanalesphd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT mariaagutierrezstampamdphd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT beatriznafriabsc analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion AT ralfjunkermd analysisofsarscov2reversetranscriptionquantitativepolymerasechainreactioncyclethresholdvaluesvisavisantisarscov2antibodiesfromahighincidenceregion |
_version_ |
1717369188962533376 |
spelling |
doaj-d19d07a29ca649b6aa785dc6db12940e2021-09-25T05:05:25ZengElsevierInternational Journal of Infectious Diseases1201-97122021-09-01110114122Analysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence regionRobert Markewitz, MD0Antje Torge, PhD1Klaus-Peter Wandinger, MD2Daniela Pauli, MD3Justina Dargvainiene4Andre Franke, MD5Luis Bujanda, MD, PhD6José Maria Marimón, PharmD7Jesus M. Banales, PhD8María A. Gutierrez-Stampa, MD, PhD9Beatriz Nafría, BSc10Ralf Junker, MD11Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel, Lübeck, Germany; Corresponding author: Robert Markewitz, MD, Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Ratzeburger Alle 160, 23560 Lübeck, Germany. Tel.: +49 451/50016315.Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel, Lübeck, GermanyInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel, Lübeck, GermanyInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel, Lübeck, GermanyInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel, Lübeck, GermanyInstitute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel & University Hospital Schleswig-Holstein, Kiel, GermanyDepartment of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital, San Sebastián, Spain; National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, “Instituto de Salud Carlos III”), University of the Basque Country (UPV/EHU), San Sebastián, SpainBiodonostia Health Research Institute, Infectious Diseases Area, Respiratory Infection and Antimicrobial Resistance Group, Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Microbiology Department, San Sebastián, SpainDepartment of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital, San Sebastián, Spain; National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, “Instituto de Salud Carlos III”), University of the Basque Country (UPV/EHU), San Sebastián, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, SpainOsakidetza, OSI Donostialdea, Altza Primary Care; Biodonostia Health Research Institute, San Sebastián, SpainClinical Biochemistry Department, Biodonostia Health Research Institute Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation. San Sebastián, SpainInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel, Lübeck, GermanyAbstract:: Objectives: To examine the relationship between antibody status and cycle threshold (Ct) values, the prognostic value of the latter for COVID-19 patients, and the inter-assay comparability of SARS-CoV-2 Ct values. Methods: In 347 COVID-19 inpatients, SARS-CoV-2 Ct values (via reverse transcription-quantitative polymerase chain reaction) on admission were compared between 2 assays and correlated with the antibody response (in the course of the disease), the clinical course and the time since onset of symptoms. Results: Ct values for 2 of 3 target genes showed significant differences between the 2 assays used (P=0.012 and P<0.0001). Ct values were significantly higher for antibody positive patients (P<0.0001) and positively correlated with the amount of time since onset of symptoms (R: 0.332–0.363; P<0.001). Patients with fatal outcomes showed higher viral loads than survivors (P<0.0001). Conclusions: Ct values depend strongly on assay used and target gene examined and should not be used as quantitative values to guide therapeutic or diagnostic decisions. The inverse association between antibody status and viral load suggests that antibodies contribute to the elimination of the virus, independent of the outcome, which is influenced by the viral load on admission and might depend more strongly on other parts of the immune response.http://www.sciencedirect.com/science/article/pii/S1201971221005701SARS-CoV-2COVID-19RT-qPCRCt valueanti-SARS-CoV-2 antibodies |